Abstract 1826P
Background
The global incidence of breast cancer is increasing, highlighting the need for attention not only to treatment but also to long-term survivorship issues. Osteoporosis, an age-related bone disorder, presents a significant concern for patients with breast cancer due to its potential impact on morbidity and mortality. This Korean nationwide cohort study aimed to investigate the occurrence and risk factors of osteoporosis among patients with breast cancer, with a specific focus on gender disparities.
Methods
Using data from the Korean National Health Insurance claim database, we identified individuals diagnosed with ductal carcinoma in situ or breast cancer as their primary diagnosis between 2009 and 2015. Patients diagnosed with osteoporosis were determined based on ICD-10 codes (International Classification of Disease) and medication prescriptions. Propensity score matching was performed to minimize confounding variables.
Results
Among 299 male and 80362 female breast cancer patients, a higher prevalence of osteoporosis was observed in females (n=13423(16.7%) vs n=15(5.0%)). Endocrine therapy was associated with an increased risk of osteoporosis, particularly among females (HR 6.37, 95%CI, 3.74-10.89, p<0.001). Age, steroid medication use, and comorbidity burden were also identified as significant risk factors for osteoporosis. Adjusting other variables, females diagnosed with osteoporosis had a higher incidence of only hip or vertebral fractures compared to males (HR 3.96, 95%CI, 1.24-12.64, p=0.020). While overall fracture incidence was higher in males before matching, gender differences were not significant after propensity score matching.
Conclusions
In conclusion, our study highlights the importance of proactive screening and management of osteoporosis in breast cancer patients, with a focus on gender-specific risk factors. These findings emphasize the necessity of comprehensive bone health assessment and preventive measures to improve long-term outcomes and quality of life for breast cancer survivors. Further research is warranted to elucidate the underlying mechanisms of gender differences in osteoporosis risk and evaluate the effectiveness of targeted interventions in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1874P - Time to vomiting after chemotherapy in association with number of emetic risk factors among breast cancer patients receiving highly emetogenic chemotherapy
Presenter: Winnie Yeo
Session: Poster session 12
1875P - Real-world evidence of ribociclib induced liver toxicity in patients with breast cancer: A multi-center experience
Presenter: Onur Bas
Session: Poster session 12
1877P - Adverse effects (AEs) of trastuzumab deruxtecan (T-DXd) in solid tumours: A meta-analysis
Presenter: Neha Pathak
Session: Poster session 12
1878P - Efficacy of surgical gloves (SG) as compression therapy to prevent oxaliplatin-induced peripheral neuropathy (PN): The ELEGANT trial
Presenter: Aurélia JOUREAU-CHABERT
Session: Poster session 12
1879P - Effectiveness of intravenous fosnetupitant & palonosetron for cinv prophylaxis in patients receiving highly emetogenic chemotherapy regimens: Subgroup analysis from a phase IV Indian study
Presenter: Arun Kumar Verma
Session: Poster session 12
1880P - Antiemetic prophylaxis during chemoradiation: Sub-study of the GAND-emesis trial identifying dosimetric predictors for vomiting
Presenter: Anika Johannsdottir
Session: Poster session 12
1881P - Enhancing chemotherapy-induced nausea and vomiting management: Insights into guideline adherence and patient outcomes
Presenter: Suresh Attili
Session: Poster session 12
1882P - Awareness of chemotherapy induced nausea and vomiting and adherence to guidelines: A multinational and multicenter survey
Presenter: Ricardo Caponero
Session: Poster session 12
1883P - Impact of geriatrician-implemented Interventions on chemotherapy (CT) delivery in vulnerable elderly patients with early or advanced solid tumors: The GIVE trial
Presenter: Emanuela Risi
Session: Poster session 12
1884P - Development and validation of a prediction tool for severe treatment-related toxicities in older cancer patients on systemic treatment (TR-TRM)
Presenter: Wendy Chan
Session: Poster session 12